Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Shares in pharmaceutical giant Eli Lilly (LLY:NYSE) have put in an outstanding performance over the last 12 months rising 71.4% to the $539 mark to become the world’s largest drugmaker by market value.Much of the excitement around the stock has been driven by new treatments for two of the globe’s biggest public health issues in obesity and Alzheimer’s. The company announced results in July from a late-stage trial showing its Alzheimer’s treatment Donanemab had a big impact on memory loss and cognitive decline.
Diabetes and weight loss treatment Mounjaro is also capturing the market’s imagination. Having been approved to treat diabetes in 2022, a trial in April revealed it also cut body weight significantly and it is expected to be greenlit as an obesity treatment later in the year.
Momentum has been sustained by its recent second-quarter results. On 8 August, the company raised its full-year revenue guidance to between $33.4 billion and $33.9 billion, up from the previous forecast of $31.2 billion to £31.7 billion.
The company posted an 85% jump in second-quarter earnings year-on-year in part supported by strong sales in breast cancer pill Verzenio and type-two diabetes drug Jardiance.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.